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Cationic antimicrobial peptides (AMPs) are important innate immunity factors contributing to 
the clearance of invading pathogens and immunomodulating immune responses. In this thesis, 
the focus is on AMPs of the cathelicidin family, i.e. the human LL-37 and the canine K9CATH. 
These peptides are positively charged at neutral pH and amphipathic in nature, making them 
prone to interact with negatively charged bacterial membranes. In this thesis, I have studied i) 
how the interaction between AMPs and bacteria can be modified by alterations of the LPS-
structure of the bacteria and ii) how the host can regulate the function of AMPs, via a post-
translational modification designated citrullination.  
In part 1 of the thesis, I studied the potential cross-resistance between colistin and LL-37 in K. 
pneumoniae. Colistin is a cationic polypeptide antibiotic that shares a similar membrane-
binding mechanism with LL-37; i.e. they both target the negatively charged components of the 
bacterial membrane. Resistance to colistin has appeared in bacteria due to modifications in the 
lipopolysaccharide (LPS) structure by reduction of the negative surface charge. The hypothesis 
of cross-resistance between colistin and LL-37 still remains debatable. In Paper I, we studied 
two clinical isolates of Klebsiella pneumoniae (Kpn), with similar genetic background but with 
different susceptibility to colistin. The colistin-resistant isolate (Col-R) had an insertion 
element in the mgrB gene, which caused the resistant phenotype. Interestingly, the Col-R 
isolate was more resistant to LL-37 in contrast to the colistin-susceptible isolate (Col-S) but 
only at concentrations above 50 µg/ml. However, there was no significant survival differences 
between Col-R and Col-S isolates in blood, serum nor in a zebrafish infection model. The 
findings of this study suggest that cross-resistance most likely plays a minor role during 
physiological conditions in vivo, where lower levels of LL-37 are present. 
In part 2 of the thesis, I studied how the host, via citrullination, could affect the function of 
AMPs in various contexts. Peptidyl arginine deiminases (PADs) catalyze the conversion of the 
positively charged arginine residues into neutral citrulline residues in a process called 
citrullination or deimination. Notably, citrullination reduces the net charge of proteins and 
peptides and could thus, affect the biological functions of AMPs. Citrullinated LL-37 has not 
been detected in human samples and the knowledge on the functional and biophysical 
consequences of citrullination is limited. Paper II, describes a series of experiments 
characterizing the presence of citrullinated LL-37 in human bronchoalveolar lavage (BAL) 
fluid from the airways of healthy donors after exposure of LPS. We identified both native LL-
37 and different variants of citrullinated LL-37 in the BAL samples. Citrullinated LL-37 had 
no antibacterial activity against Escherichia coli, interacted differently with LPS and had 
reduced affinity to anionic phospholipids. Finally, a net positive charge was shown to be 
essential for the antimicrobial activity of LL-37.  
Finally, I expanded the studies on citrullination to another AMP, the K9CATH peptide, which 
is the only cathelicidin found in dogs. It has a broad antimicrobial activity against both gram-
positive and gram-negative bacteria, it binds to LPS and has anti-inflammatory functions. 
Similarly, to LL-37, K9CATH has a positive net charge at neutral pH due to lysine and arginine 
residues. PAD enzymes are found in all organisms studied, including dogs. However, it is 
unknown whether K9CATH is a substrate to PAD enzymes. In Paper III we report the that 
recombinant PAD2 and PAD4 citrullinated K9CATH at different degrees. Citrullination 
abrogated the antibacterial activity against gram negative bacteria and reduced the peptide’s 
anti-inflammatory activity on LPS-induced macrophage stimulation.  
In conclusion, my studies provide information on the interactions of cathelicidin peptides with 
bacterial membranes and the different host/microbe mechanisms, regulating the activity of the 
peptides. This information provides a platform for future research on the role of citrullination 
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Mammals have evolved multiple defense mechanisms to survive in an environment filled of 
pathogens. Our immune system consists of a variety of cells and molecules that are divided 
into two systems, the innate and the adaptive immunity. Both systems are important in securing 
the integrity and defend the health of our bodies against infections and tissue injuries within 
the host. Innate immunity is found in every living organism, from prokaryotes to eukaryotes. 
It provides instant protection against intruders and requires less energy to spend. On the other 
hand, the adaptive immune system is important in vertebrates and most developed in mammals. 
It is unique since it has a memory that recognizes the already encountered pathogens and 
provide an enhanced protection against recurrent infections. Both systems are highly 
interconnected and interactions between the two systems are needed for a healthy and balanced 
immune response.  
However, some pathogens have evolved ways of evading the mechanisms of our immune 
systems, resulting in diseases and thus the need of exogenous treatment approaches, such as 
antibiotics. In the past decades, the extensive use of antibiotics eventually led to emergence of 
resistance in some bacterial strains and this made it challenging to treat infections. Most 
importantly, public health concerns are increasing with the emergence of multidrug resistant 
(MDR) strains and their spread in both human and animal populations (1, 2). This has directed 
the scientific communities to search for safe alternatives to antimicrobials that are active against 
MDR strains, and not harmful to host cells (3). Endogenous antimicrobial peptides (AMPs) 
constitute a part of innate immunity and are known for their multiple functions against 
pathogens, such as direct killing or indirect killing by regulating the immune response to 
infections. Therefore, AMPs represent an attractive platform to develop novel therapies (3, 4). 
In addition, approaches of host-directed therapy by boosting the production of effective 
immune factors are gradually getting attention from the scientific community (5, 6).  
The present thesis will discuss the innate immune system and AMPs. This thesis shed lights on 
innate immunity and AMPs and how AMPs interact with bacterial membranes. The first part 
covers the potential probability of cross-resistance between conventional antibiotics (with 
antimicrobial peptides’ origin) with host antimicrobials. The second part describes how post-
translational modifications (PTM), i.e. citrullination, affect the structure and functions of 





2 THE INNATE IMMUNE SYSTEM  
The innate immune system is the first line of defense that can be rapidly activated by invading 
microorganisms. It consists of several barriers and effector cells empowering it with the 
capacity to defend, fight back and resolve infections successfully. Mechanical barriers, such as 
intact skin, the peristalsis movement of the gut and the nasal cilia are essential to hamper the 
ability of microbes to attach to the linings of the body. Chemical barriers, including sweat, lung 
surfactant, gastric acids and the mucus lining of the mucosal epithelia, are beneficial to inhibit 
colonization of unwanted microbes in the body. These linings are also populated with 
commensal microorganisms, which play a role in protecting the host from pathogenic microbes 
by competing for space and nutrition (7).  
2.1 INNATE IMMUNE CELLS 
The innate immune system is also armed of cellular and soluble components that are highly 
effective in eliminating pathogens or stopping them from spreading throughout the body. A 
majority of these cells are hematopoietic cells (except for epithelial cells) and they belong either 
to the myeloid lineage, such as granulocytes and macrophages, or to the lymphoid lineage, such 
as natural killer cells and innate lymphoid cells. They fight infections by direct killing, 
including phagocytosis and cytotoxicity or bacterial elimination via secreted effector 
components, such as AMPs and cytokines (8). Some immune cells have special functions, e.g. 
dendritic cells, which plays a central role in activating the adaptive immune system through 
presenting foreign antigens to B- and T-cells (9).  
2.1.1 Epithelial cells 
A part of the cellular compartment of innate immunity is composed of epithelial cells that are 
lining e.g. the gut and the respiratory system. Epithelial cells are connected to each other by 
tight junctions sealing the inner organs from invading microbes. In addition, they have 
receptors recognizing common conserved structures of pathogens, i.e. microbe-associated 
molecular patterns (MAMPs) (7, 10). These receptors are called pattern recognition receptors 
(PRRs) and include the toll like receptors (TLRs) as well as the intracellular receptors 
Nucleotide Oligomerization Domain (NOD)-like receptors. Activation of TLRs or NOD-like 
Receptors (NLRs) leads to release of cytokines, chemokines and AMPs, which collectively 
activate the adaptive immune-system, but also directly kill the invading bacteria by virtue of 




2.1.2 Polymorphonuclear Granulocytes 
The polymorphic nuclei and granules in the cytoplasm are the main characteristics of 
granulocytes. Neutrophils, eosinophils, basophils and mast cells are all considered 
granulocytes. Neutrophilic granulocytes or “neutrophils”, are short-lived and they are the first 
cells recruited to the site of infection. They kill microbes intracellularly by engulfment and 
phagocytosis and they also release the content of the granules, such as AMPs and proteases, 
that help degrading the cell wall of microbes leading to their death. Neutrophils can also 
directly kill bacteria by generating reactive oxygen species (ROS) and nitric oxide (NO), which 
act as toxic substances on the bacterial membrane leading to its disruption (12, 13). 
Furthermore, during inflammatory conditions, neutrophils undergo a process of cell death 
leading to the formation of neutrophil extracellular traps (NETs). NETs are mainly composed 
of released DNA with a negative charge and decorated with positively charged proteins and 
peptides, including histones and AMPs, such as LL-37 (14).  
2.1.3 Macrophages 
The word “macrophage” means “big eater”, i.e. they phagocytose invading microbes, apoptotic 
cells, cell debris and foreign entities. Macrophages are found circulating in the blood as 
monocytes but also reside in the parenchyma of tissues, where they recognize pathogens and 
maintain homeostasis in the tissues. Resident macrophages take various forms and names based 
on the tissue, where they reside, such as Kupffer cells in the liver and microglia in the brain 
and the spinal cord. Macrophages play an important role in the regulation of inflammation in 
order to avoid tissue damage and fibrosis due to persistent or excessive inflammation. 
Classically activated macrophages (M1-type) have the ability to increase inflammation, 
whereas alternatively activated macrophages (M2-type) are involved in anti-inflammatory and 
tissue repair processes (15). Macrophages have additional key functions in priming the adaptive 
immune-system through presenting antigens to lymphocytes and by secreting cytokines (16, 
17). 
3 INNATE IMMUNE RECOGNITION  
The innate immune system can sense abnormal events, for example tissue damage or infections 
through PRRs (7), including TLRs and NLRs that are encoded in the germline of immune cells 
and epithelial cells. These receptors recognize conserved pathogen-associated molecular 
patterns (PAMPs) that are shared by large group of pathogens, such as microbial unmethylated 
DNA (CpG) or membrane components such as lipopolysaccharide (LPS) and subsequently, 
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trigger downstream effector mechanisms (7). Upon microbial exposure, these receptors initiate 
intracellular activation leading to secretion of pro-inflammatory cytokines and chemokines to 
attract immune cells to a site of infection. In addition, the innate immune system detects 
damage-associated molecular patterns (DAMPs) that are released after injury due to cell lysis 
and tissue damage that occur in the context of both infectious and sterile-tissue injury. The 
release of DAMPs activates PRRs and its downstream inflammatory pathway (18). The most 
important aspect of innate immune recognition is the ability to discriminate between self and 
non-self-antigens. Innate immune cells, such as NK cells can detect the host’s own cells that 
are not healthy (infected with viruses or cancerous cells) and attack them. To avoid an immune 
response against host cells, this process is highly controlled through an inhibitory system using 
MHC class I molecules , which is upregulated on healthy cells and downregulated in infected 
cells (19).  
4 ANTIMICROBIAL PEPTIDES (AMPS) 
In mammals, AMPs play an important role in the defense mechanisms of the innate immune 
system against bacterial, fungal and viral infections. They are expressed by epithelial cells in 
the respiratory system, gastrointestinal tract and urogenital system. Furthermore, AMPs are 
expressed in immune cells such as neutrophils and macrophages (20). Most AMPs share some 
common characteristics such as i) the short length of 12 -50 amino acids residues, ii) a positive 
net charge and iii) an amphipathic character (one side is hydrophobic and the other side is 
hydrophilic or charged) (21, 22). Most AMPs provide immunity through direct killing of 
pathogens by disturbing the integrity of the microbial membrane. They also exhibit 
immunomodulatory activities, such as recruiting immune cells to the site of infection, 
neutralizing the inflammatory activity of LPS, stimulating wound healing and also stimulation 
of epithelial release of inflammatory factors (21). Defensins and cathelicidins are the two main 
families of AMPs in mammals (21). The structure of defensins is defined as anti-parallel β-
sheets, which are stabilized with three intramolecular disulfide bonds (23). The defensins are 
subdivided into three groups; a-defensins are mainly expressed in neutrophils and Paneth cells 
of the small intestine, and b-defensins are found in epithelial cells. In addition, theta defensins 
are circular mini-defensins that are present in leukocytes of rhesus monkeys, but not expressed 
in humans due to a pseudo-gene (23, 24).  
The other main AMP-family in mammals is the cathelicidin peptide family, which share a 
common N-terminal cathelin domain and an antimicrobial C-terminus of diverse sequence and 
length (25). Mature cationic peptides are generated by cleavage of the C-terminal domain and 
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they vary in their secondary structure; some adopt an a-helical structure, such as LL-37, 
whereas other peptides form b-sheet structures, such as the cyclic protegrin (26, 27). 
Cathelicidins have been described in many mammals, such as pigs, rabbits, mice and dogs. In 
humans, there is one cathelicidin gene (CAMP), which encodes hCAP-18 as a pro-protein, 
which is subsequently cleaved to release the mature peptide LL-37. This human peptide is 
found in granules of neutrophils and also expressed in epithelial cells (28).  
In addition to defensins and cathelicidins, other small classes of peptides enriched for specific 
amino acids can be distinguished in mammals. It should also be mentioned that there are also 
antimicrobial proteins, such as lactoferrin, lysozyme and lipocalin (29, 30). However, in this 
review, the focus will be mainly on the human cathelicidin LL-37 and its orthologue in dog 
(K9CATH). 
4.1 THE HUMAN CATHELICIDIN (LL-37) 
The human cathelicidin LL-37 is expressed in both myeloid cells and epithelial cells and are 
encoded by the cathelicidin antimicrobial peptide (CAMP) gene. The gene is translated into the 
18 kDa inactive proform; human cationic antimicrobial peptides (hCAP-18). Upon activation, 
hCAP-18 is cleaved extracellularly by proteinase-3 (31) leading to the generation of a mature 
peptide of 37 amino acid residues, with two leucine residues at the N-terminal end, hence the 
name LL-37 (32). LL-37 has a positive net charge of +6 at neutral pH due to the 11 basic 
residues of arginine and lysine. The secondary structure of LL-37 is random coil in pure water, 
but adopts an a-helical structure in the presence of phospholipid liposomes or lipid A (33) or 
in salt solution mimicking the body fluids, such as plasma and intracellular fluid (34). The 
antibacterial activity has been shown to correlate with the secondary structure of LL-37 (34). 
The distribution of the hydrophilic and hydrophobic residues gives the peptide its amphipathic 
character, which facilitates the interaction with target membranes. 
4.1.1 Expression and regulation of LL-37 
LL-37 is expressed in neutrophils and immune cells, such as monocytes, macrophages, NK 
cells (35), and mast cells. In addition, it is expressed in epithelial cells in direct contact with the 
environment, such as in the skin, gastrointestinal tract, lungs as well as in eccrine and salivary 
glands (16, 23). Notably, mature LL-37 peptide can be released from granulocytes and 
macrophages in response to infection. During inflammation LL-37 synthesis is upregulated in 
the skin, testis and in airway epithelia (33). The regulation of LL-37 expression is not only 
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controlled by inflammatory pathways, but also through vitamin D signaling and by 
endoplasmic reticulum (ER) stress (36, 37). 
4.1.2 Biological activities of LL-37 
LL-37 has a broad spectrum of antimicrobial activity, which has been demonstrated against 
gram negative bacteria, such as S. typhimurium, E. coli, and P. aeruginosa, as well as against 
gram positive bacteria including L. monocytogenes, S. aureus and S. epidermidis (38). 
Additionally, LL-37 shows antifungal activity against C. albicans and anti-viral properties 
against several viruses, including influenza virus and HIV-1 (39). Apart from its antimicrobial 
properties, LL-37 has additional functions, such as chemotactic activity on neutrophils, 
induction of cytokines and chemokines from epithelial cells, wound healing properties and 




Fig. 2. Biological activities of the human cathelicidin LL-37 at epithelial surfaces. LL-37 
participates in the recruitment of neutrophils and other circulating cells to the site of infections. 
LL-37 contributes to killing of invading pathogens and promotes repair of damaged tissue by 
inducing re-epithelialization and angiogenesis. Adapted from (26). 
4.2 THE CANINE CATHELICIDIN (K9CATH) 
AMPs play an important part of innate immunity in dogs. The two main families of peptides in 
dogs are composed of six defensins and one cathelicidin and they exhibit antibacterial activity 
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against bacteria and fungi. The mature peptide K9CATH is expressed in neutrophil granules 
and is made of 38 amino acid residues and shows 46% similarity to the human LL-37 (40) 
(Table 1). K9CATH show features of common cationic AMPs, such as positive charge (+6) at 
neutral pH and an a-helical structure in lipid-mimicking environments (40). It is highly 
effective against gram negative bacteria, such as E. coli, P. aeruginosa, as well as against gram 
positive bacteria, such as S. aureus, and methicillin-resistant Staphylococcus. pseudintermedius 
and to a lesser extent against methicillin-resistant S. aureus. Furthermore, it is active against 
yeast, such as Malassezia pachydermatis (41). In addition, K9CATH has been shown to inhibit 
LPS-induced macrophage activation (42). It also indirectly stimulates chemotaxis of immune 
cells, such as macrophages by upregulating expression of CXCL10 (42).  
Bacterial pneumonia (bacterial infection of the lung) is a common clinical problem in dogs 
(43). Bacterial pneumonia in dogs are often caused by E. coli, K. pneumoniae, Pasteurella spp, 
Mycoplasma spp, and S. pseudintermedius (43). Treatment is based on the severity of the case, 
with antibiotics, such as amoxicillin, amoxicillin-clavulanic acid or doxycycline (43, 44). 
However, the frequent use of antibiotics may have contributed to the emergence of multi-drug 
resistant strains in dogs and humans worldwide. Bacterial resistance makes treatment more 
difficult and this urges the need to acquire alternative strategies to treat infections caused by 
multidrug-resistant bacteria (45). Both canine defensins and the single cathelicidin K9CATH 
are effective against methicillin-resistant strains (41). Thus, AMPs have been studied as 
alternative candidates for treatment, since the resistance against AMPs so far is low in these 
bacterial species (41). 
 
Peptide Sequence Length Charge 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 37 +6 
K9CATH RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS 38 +6 
Table 1. Sequences of the human and canine cathelicidins. 
5 ANTIMICROBIAL MECHANISMS OF ACTION 
Similar to most cationic antimicrobial peptides, LL-37 kills bacteria by disrupting their 
membrane, resulting in lysis (28). Most of the antibacterial activity of LL-37 against bacteria 
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is attributed to its cationicity and hydrophobicity. The initial interaction with bacteria is through 
the electrostatic interaction of the positively charged peptide residues with the negatively 
charged components of the outer leaflet of the bacterial membrane, such as LPS or cardiolipin 
in gram negative bacteria or with lipotechoic acid (LTA) on gram positive bacteria. The 
hydrophobic side of LL-37 interacts with the hydrophobic headgroups of the lipids of the 
bacterial membrane, leading to a disturbed integrity of the membrane. The LL-37 peptide 
accumulates on the membrane according to the carpet-model (46), or form toroidal pores in the 
lipid bilayer (47). However, there is still a debate on the exact mechanistic model that the 
peptide utilizes to kill bacteria. 
5.1 INTERACTIONS OF AMPS WITH LPS  
The Gram-negative cell envelope is consisting of three layers, the inner membrane, the 
periplasmic membrane, and the outer membrane. The inner or the cytoplasmic membrane is 
usually composed of phospholipid bilayers. The periplasmic layer is the middle layer 
containing a thin matrix of peptidoglycan. The outer membrane is made of an inner leaflet 
composed of phospholipids and the outer leaflet is mainly composed of LPS (48). LPS, also 
known as endotoxin, is generally comprised of three parts, the inner hydrophobic part is lipid 
A, the middle part is the core oligosaccharide (core-OS), and the outer hydrophilic part is a 
chain of repeating units of O polysaccharide (O-antigen) (49). Most clinical strains of 
Escherichia coli (E. coli) have LPS, consisting of all three parts (smooth LPS), other strains, 
such as K-12, lack the O-antigen (rough LPS) and some strains lack both O-antigen and whole 
or part of the core-OS (deep rough LPS) (50). LPS functions as a protective layer that support 
viability of bacteria. LPS released from bacteria interacts with innate immune cells and can 
trigger an immune response. Furthermore, LPS could induce an excessive inflammatory 
response that might lead to the development of septic shock syndrome, which is a life-threating 
disease (51). LPS in general is an anionic molecule and so considered as an initial target for the 
activity of cationic AMPs due the electrostatic interaction. Apart from acting directly on the 
bacterial membrane leading to bacterial killing, it is widely known that AMPs neutralize the 
effects of released LPS by either a direct binding to the LPS molecule, preventing it from 
activating immune cells, such as macrophages (52). A recent study revealed that the LPS 
structure has a role in the sensitivity of bacteria, such as E. coli, to the activity of cationic 
AMPs. LPS mutant E. coli strains lacking sugar structures in the inner OS-core were more 
susceptible to a set of helical AMPs, including Cap18 a rabbit orthologue to human LL-37 
peptide, compared to the wild-type strain, indicating the importance of LPS for the activity of 




6 IMMUNOMODULATORY ACTIVITIES OF 
CATHELICIDINS 
AMPs including cathelicidins are additionally known as host defense peptides since they take 
part in the modulation of immune responses. Depending on the context, cell type and 
inflammatory stimuli, cathelicidins have either pro-inflammatory or anti-inflammatory 
properties (54). In addition, they chemoattract immune cells to the site of infections and they 
direct cell differentiation of immune cells. In this thesis we focus on the anti-inflammatory 
functions.  
6.1  ANTI-INFLAMMATORY FUNCTIONS 
Many bacterial membrane components, such as LPS of gram negative bacteria and lipoteichoic 
acid of gram positive bacteria, are ligands to TLR4 and TLR2, respectively (55). They activate 
TLR signaling, resulting in proinflammatory activation of leukocytes. Due to their overall 
negative charge LPS binds to cathelicidins such LL-37, K9CATH, mCRAMP and PMAP-36 
and prevents production of pro-inflammatory cytokines such as LPS-mediated TNF-a 
production in leukocytes (56). LL-37 reduces LPS-induced nitric oxide (NO) released from 
macrophages and also protects mice injected with lethal concentrations of LPS (57). 
Furthermore, cathelicidins inhibit endotoxin-mediated up-regulation of pro-inflammatory 
cytokines, such as IL-6, IL-1b, and INFg (56). Thus, interaction of cathelicidins and TLR 
ligands plays an important role in modulating pro-inflammatory responses via TLR activation.  
7 COLISTIN  
Colistin is a polypeptide antibiotic originally isolated from Paenibacillus polymyxa subsp. 
colistinus bacteria, which is found in soil (58). Colistin, also known as polymyxin E, is one of 
the primary classes of antibiotics known as polymyxins. Polymyxins consist of different 
compounds classified from A to E. It is effective against many Gram-negative bacteria by 
disturbing the integrity of the bacterial outer membrane. Colistin, which is positively charged, 
interact in an electrostatic mode with the negatively charged LPS and phospholipids of the 
bacterial membrane, where it displaces Mg2+ and Ca2+ from the cationic binding sites (59). This 
results in a detergent effect that disturbs the membrane integrity leading to leakage of cell 
content and eventually death of the bacteria (60). In addition, similar to AMPs, polymyxins 
bind and neutralized LPS molecules (61). In the clinic, colistin is considered to constitute the 
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last line resort in the treatment of infections caused by multidrug-resistant gram negative 
bacteria, such as E. coli, K. pneumoniae and A. baumannii (62).  
7.1 CROSS-RESISTANCE BETWEEN LL-37 AND COLISTIN  
Acquired resistance to colistin has been detected in many bacterial species. Resistance is 
primarily due to modifications of the LPS molecules, which lead to decreased overall negative 
charge and subsequently reduced binding affinity of colistin to the bacterial outer membrane 
(63).  In recent years, an increasing number of colistin resistant pathogens has emerged in many 
parts of the world, with serious consequences for patients and health-care systems on a global 
scale. In addition, it has been speculated that widespread colistin therapy can induce cross-
resistance towards AMPs. The consequences of expanded AMP-resistance among these 
bacteria could lead to even more severe infections, when the host’s immune system becomes 
blunted. Indeed, a study on the human pathogen A. baumannii revealed a positive correlation 
between resistance to colistin and resistance to LL-37 (64). Colistin and LL-37 are both AMPs 
and share a similar binding mechanism with the bacterial cell wall. It should, however, be noted 
that the clinical implications of this potential cross-resistance are not clearly elucidated. 
Nevertheless, a detailed understanding of the molecular basis of the potential cross-resistance 
between AMPs and clinically used drugs, such as colistin, is important, as it can enhance the 
development of more efficient therapeutic AMPs. 
8 CITRULLINATION  
Citrullination or deimination of a peptide or protein is a post-translational modification (PTM) 
process, where the cationic arginine residues are converted into neutral citrullines in proteins 
(Fig. 3) (65). Citrulline is a non-coded amino acid and there is no corresponding tRNA. The 
enzymatic conversion of arginine to citrulline results in the loss of positive charge and an 
increase in mass of approximately 1 Da (66). This modification can influence the overall 
charge, the isoelectric point, the ionic and hydrogen bonds within a peptide or protein, as well 
as the interactions of peptides or proteins with other molecules (65).  
8.1 PEPTIDYLARGININE DEIMINASE ENZYMES (PADS)  
The citrullination process is catalyzed by the calcium-dependent peptidylarginine deiminase 
enzymes (PADs). In humans, there are five isotypes of PADs (PAD 1, 2, 3, 4, and 6) that are 
distributed throughout the body in a tissue-specific manner. The PAD-family is highly 
conserved and their encoding genes are clustered at chromosome 1p36.1, within a 300 kb 
region (67). These enzymes have different substrate specificity and tissue-specific expression. 
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PAD1 is mainly expressed in epidermis and uterus and one of its substrates is keratin K1. PAD1 
is involved in the cornification of epidermal tissues. PAD2 is the most widely expressed 
member of the PAD family throughout the body. It is expressed in skeletal muscle, brain, 
spleen, secretory glands, neutrophils and macrophages (67, 68). The most common substrates 
for PAD2 are the myelin basic protein and vimentin in muscles and macrophages. PAD3 was 
detected in hair follicles and epidermis and it is involved in regulating epidermal functions 
through deiminiation of filaggrin and trichohyalin. PAD4 is found in immune cells, such as 
neutrophils, eosinophils and monocytes. It is localized mainly in the nucleus and citrullinates 
histones and other nuclear proteins, thus playing a role in gene regulation and NET-formation. 
PAD6 is expressed in ovaries, testis and eggs (65, 67). Overall, protein citrullination by PAD 
enzymes is involved in several physiological processes in gene regulation, innate immunity 
and reproduction systems, as well as in skin keratinization. Moreover, studies have shown the 
involvement of PADs in pathological conditions, such as tumorigenesis and autoimmune 
diseases, such as rheumatoid arthritis, Alzheimer disease and multiple sclerosis (69).  
 
Fig.3. Citrullination of peptidylarginine by PAD. The arginine residue is converted to citrulline 
residue. Adapted from (67) 
8.2 CITRULLINATION OF LL-37 
Under inflammatory conditions, the human cathelicidin LL-37 is exposed to the post-
translational activity of PADs. The possibility of citrullination of LL-37 by PAD-enzymes was 
first described in vitro by PAD2 and PA4 (70). LL-37 was citrullinated after incubation with 
recombinant PAD2 and PAD4. Both enzymes caused different degrees of citrullination on LL-
37; PAD2 citrullinated all five arginine residues, whereas PAD4 only citrullinated three 
arginine residues at position 7, 29 and 34. Citrullination of LL-37 reduced the antibacterial 
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activity against bacteria associated with chronic obstructive pulmonary disease (COPD) 
including non-typable H. influenzae, S. pneumoniae, and S. aureus. Notably, citrullination did 
not affect the antimicrobial activity against P. aeruginosa to the same extent as the other 
bacteria. Citrullinated LL-37 caused leakage in anionic liposomes similar to the native peptide, 
suggesting that a reduction in charge was not fully detrimental for membrane disturbance by 
LL-37 (70). In addition, citrullination altered the immunomodulatory activities of LL-37 both 
in vitro and in vivo. A strong increase in chemotactic activity against macrophages was 
observed with citrullinated LL-37 compared to the native peptide, while an impaired capacity 
to block LPS-induced inflammatory cytokines in macrophages was detected (70, 71). 
Furthermore, citrullination of LL-37 abrogated its ability to prevent endotoxic shock in a mouse 
model of sepsis (71). The mechanism was shown to be caused by the inability of citrullinated 
LL-37 to inhibit the release of proinflammatory cytokines from macrophages stimulated by 
bacterial TLR ligands, such as LTA and poly(I:C) (71).  
LL-37 has also been shown to facilitate delivery of free DNA from both pathogens and dying 
host cells to intracellular TLR-9 in human plasmacytoid dendritic cells (72, 73). In relation to 
this finding, a recent study reported that citrullinated LL-37 could not bind to the negatively 
charged DNA, which resulted in  a reduced activation of dendritic cells and macrophages in 
response to bacterial DNA (74). This suggests that citrullination of LL-37 downregulates the 
immune response to cell-free DNA. Another recent study revealed the presence of auto-
antibodies against LL-37 and its post-translationally modified forms, such as citrullinated and 
carbamylated LL-37 in sera and synovial fluid of psoriasis and psoriatic arthritis patients (75). 
Taken together, citrullination of LL-37 has direct effects on the regulation of innate immune 
responses. Therefore, it is important to further investigate the role of citrullination and its 
relation to diseases, such as rheumatoid arthritis, psoriasis, COPD and infections with 
pathogens.  
8.3 CITRULLINATION IN DOGS (CANINES) 
There are strong indications PAD enzymes exist in all mammals and they are involved in many 
physiological and pathological processes (67). A recent study showed that stimulation of canine 
neutrophils with LPS from E. coli resulted in the formation of NETs, generating 
hypercitrullination of histone H3 by PAD enzymes. This suggest that citrullination of histones 
by PADs is essential for cellular events during NETosis (76). In addition, PAD2 has been 
documented to be expressed in mammary tissues of female dogs. PAD2 citrullinated histones 
from mammary epithelial cells, suggesting a role in the regulation of lactation genes (77). 
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However, expression of PAD2 was reduced in mammary carcinoma from dogs (78). Further 
studies are needed to study effects of citrullination of K9CATH and its regulation during 
inflammation. 
9 CONCLUSION 
Bacterial resistance to conventional antibiotics is increasing worldwide in an alarming rate to 
both human and animal healthcare. AMPs may be studied in the context of multidrug resistant 
bacteria and cross-resistance may occur between LL-37 and colistin. However, the clinical 
implications need to be further studied. In addition, the role of PTM i.e. citrullination, has 





10 AIM OF THE THESIS 
 
The general aim of this thesis is to elucidate the role of host and pathogen factors, regulating 
the interactions of the cationic antimicrobial peptides with bacterial membranes. We therefore 
set out to study the following specific aims: 
 
• To study the interactions of colistin-resistant Klebsiella pneumonia with the human 
antimicrobial peptide LL-37 and to shed light on the potential cross-resistance between 
LL-37 and the polypeptide antibiotic colistin. (Paper I) 
 
• To detect citrullinated LL-37 in human biological samples and to study the effects of 
post-translational modification (citrullination) on the bio-physical properties of LL-37 
and its interactions with bacterial membranes. (Paper II) 
 
• To evaluate whether the effects of citrullination on LL-37 can be expanded to its canine 
orthologue K9CATH and study the effects of citrullination on the interactions between 











11 MATERIALS AND METHODS 
This is a brief overview of the methods and materials used to obtain the results in Papers I, II 
and III, included in this thesis. For more detailed on the materials and methods, please refer to 
Papers I, II and III attached in this thesis. 
11.1 MATERIALS 
Bacterial strains: In Paper I we used clinical isolates of K. pneumoniae (Kpn) collected from 
Oman (n= 17). All of the Kpn isolates were resistant to carbapenems. Eight of the isolates were 
less susceptible to colistin due to mgrB-insertion and the other 9 isolates were more susceptible 
to colistin assessed by broth micro-dilution with colistin. In addition, two isolates from the 
above collection were selected and studied in depth at different conditions, these are colistin 
resistant OM124 (Col-R) and colistin sensitive OM322 (Col-S). They were selected based on 
their similar genetical background and difference in colistin sensitivity due to the presence of 
mgrB-insertion in Col-R isolate. Other strains were included in this study as controls, such as 
K. pneumoniae ATCC25955, E. coli D21 and Proteus mirabilis ATCC29245. In Paper II & 
III, we used Pasturella multocida (P. multocida) ATCC 6533 and a collection of E. coli strains 
with different LPS structures; wild type E. coli MG1655, the sequenced E. coli K-12 strain 
(DA5438) and its reconstructed LPS mutant strain (DA26796) with amino acid deletion at rfaC 
(del aa 195-199) (79), to study the antibacterial activities of LL-37 and K9CATH. 
Peptides: Synthetic native LL-37 and K9CATH peptides and their citrullinated forms were 
purchased in a lyophilized form (Innovagen, Lund, Sweden). Prior to the experimental studies, 
peptides were dissolved in 0.1% TFA in water for bacterial work or in pure water for cell 
culture work and stored in aliquots at -20 °C until further use (Paper I, II & III).  
Blood: Peripheral blood from healthy individuals was collected and used after dilution in 
RPMI-1640 medium for blood killing assays. In addition, serum was separated from blood and 
stored at -20 °C until further use for bacterial killing assay. Red blood cells from blood or buffy 
coat was also used to study hemolytic activities of AMPs (Paper II & III).  
Zebrafish: Embryos of zebrafish were injected with bacteria and used as an in vivo infection 
model. They were used to study whether the resistance to colistin modified the virulence of 
Kpn and also to test their fitness in vivo.  
Broncheoaloveolar lavage (BAL): In one of my studies, we had access to material from an 
experimental study in humans, where LPS was instilled into the lungs of healthy volunteers. 
The original data was published in (80, 81). Briefly, Bronchoscopy was used to deliver LPS (4 
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ng/kg) Escherichia coli (E. coli) 0113:H10 (Rockville, MD, USA) to lungs of healthy 
individuals. After 12 to 24 h, BAL fluid was collected and stored at -80 °C until further use.  
Cell lines: Macrophage-like cell lines were used as in-vitro model to test the effects of peptides 
on LPS-mediated cell activation. Murine macrophages RAW264.7 cells (ATCC-TIB-71) are 
extensively used since they are easy to work with, give reproducible results and have good 
phagocytic capacity. We used them specifically to study the effects of K9CATH to block LPS-
signaling and thus to provide a proof of concept for our hypothesis. In order to consider species- 
related factors, we used canine DH82 cells (ATCC CRL-10389)(82), which is derived from 
dog. Cells were seeded into 96-well cell culture plates in media supplemented with fetal bovine 
serum. After reaching confluency cells were washed once with PBS and then treated with 
peptides or LPS or a combination of treatments and supernatants were collected after 24 h and 
stored at -20 °C until further use. Supernatants were used to study levels of pro-inflammatory 
molecules, such as NO using the Griess assay or cytokines, as TNF-a using ELISA (Paper 
III). 
11.2 METHODS 
Bacterial killing assay: This method was used to study the effects of a certain drug or molecule 
on the growth or survival of bacteria. We used synthetic LL-37 peptides, K9CATH peptides, 
40% diluted blood or serum in the studies included in this thesis. Bacteria were incubated with 
selected treatments, incubated at 37 °C in a shaker, serially diluted and then plated on blood 
agar plates overnight to measure colony forming units (CFU). Bacteria with media alone were 
used as negative controls in all experiments. (Paper I, II & III) 
Zebrafish infection model: Zebrafish embryos develop innate immunity very early post 
fertilization but adaptive immunity takes longer time to develop (83). Thus, zebrafish embryos 
are good candidates to study interactions of colistin-resistant bacteria with innate immunity 
factors in an in-vivo model. In Paper I, we wanted to test whether the gain of an antibiotic 
resistance mechanism would cause a cost of fitness on Kpn strains in vivo. Therefore, we 
infected the embryos with 150-300 CFU of Col-R, Col-S or Kpn ATCC25955 as a control, 
using a microinjection procedure, where a volume of 1-2 nL was injected into the viable 
zebrafish embryo under a stereomicroscope. A group of embryos were injected with only E3 
media as negative control. Infected embryos were either digested after injection to determine 
the number of bacteria in the embryos or left incubated at 30 °C for 72 h and any signs of 




Peptide and protein extraction from BAL fluid samples: To isolate AMPs from BAL fluid, 
which is a complex matrix containing cells, salts, proteins and many other constituents, we first 
pooled BAL fluid from 10 healthy donors and centrifuged the mixture at 5000 rpm for 15 min. 
Next, supernatants were enriched for proteins and peptides using OASIS reversed-phase HLB 
columns that eliminated all salts. Proteins and peptides bound to the columns were then eluted 
with 80% acetonitrile in 0.1% TFA. Afterwards, the protein extracted samples were lyophilized 
to get rid of acetonitrile and resuspended in 0.1% TFA and stored at -20 °C until further use 
(Paper II).  
Reversed-phase liquid chromatography: This method has been used in our group for many 
years. It has primarily been used to isolate AMPs from biological complex samples separated 
into fractions based on their hydrophobicity. Briefly, the BAL peptide/protein extract (0.5 mg) 
was separated on a Vydac C8 (250 × 4.5 mm) reversed-phase column (HiChrom Ltd, UK) with 
a flowrate of 0.3 mL/min. Peptides trapped in the column were eluted with a gradient of 
acetonitrile in 0.1% TFA (0–20% for 16.6 min, 20–60% for 33.2 min and 60–80% for 66.2 
min) and fractions were collected. The absorbance was monitored at 214 nm to detect peptide 
bonds and 280 nm to detect proteins. These fractions could later be used to detect specific 
AMPs with different methods, such as dot blot analysis, utilizing specific antibodies or further 
analysis with mass-spectrometry (LC-MS/MS) to detect the composition of the fractions. 
(Paper II) 
In vitro PAD citrullination: Recombinant PAD enzymes were used in this study to 
citrullinate the synthetic K9CATH peptides. PAD enzymes require high levels of calcium in 
order to function (84). The buffer used for this experiment contained (100 mM Tris-HCl, 5 
mM CaCl2, and 5 mM DTT, pH 7.6). We selected PAD2 and PAD4 in this study, since both 
enzymes are expressed by cells in the immune system and are expected to occur in close 
proximity to AMPs in vivo (85).  Briefly, peptides (1 mg/ml) were incubated with the 
enzymes in a concentration of 50 units enzymes/mg of peptide, at different time points and 
the reaction was stopped by adding formic acid as described previously (74). Samples were 
stored at -20C until further use. Samples containing the mixture of peptides and enzymes 
were used along with LPS to study the effects of citrullination on the capacity to inhibit LPS-
mediated macrophage activation. Peptide-enzyme mixtures were also tested for citrullination 




Macrophage stimulation: Macrophage-like cell lines (murine RAW264.7 and canine DH82 
cells) were used as in-vitro model to test the effects of peptides on LPS-mediated cell 
activation. Murine RAW 267.7 macrophage-like cell-line are extensively studied cell line and 
are excellent cells to us in proof of concept studies. In order to obtain a physiological system 
relevant for the K9CATH-peptide, which is the canine orthologue of LL37, we used the 
macrophage-like DH82 cell line. This is a cell line that originates from the neoplastic cells of 
canine malignant histiocytosis (82). Cells were seeded into 96-well cell culture plates in media 
supplemented with fetal bovine serum. After reaching confluency, cells were washed once with 
PBS and then treated with synthetic peptides (5 µM) or peptide (2.5 µM) /PAD enzyme mixture 
preincubated with LPS (100 ng/ml) and supernatants were collected after 24 h and stored at -
20 °C until further use. To assess if synthetic peptides alone have any effects on LPS-mediated 
macrophage activation, cells were first stimulated with 5 μM peptides alone for 1 h, after which 
the peptides were washed away with PBS then stimulated with LPS as mentioned above. For 
all stimulation methods, supernatants were used to study pro-inflammatory molecules, such as 
NO using the Griess assay or cytokines as TNF-a using ELISA (Paper III). 
 
11.3 ETHICAL CONSIDERATIONS 
All of the studies in this thesis followed the ethical principles of the Declaration of Helsinki. 
Ethical approval was obtained from the Ministry of Health in Oman for the use of the bacterial 
isolates and the collection of (anonymized) patient data (MH/DG/R&S/32/2015) in Paper I. 
The procedure to draw blood from healthy volunteers was approved by the Regional Ethical 
Review Board in Stockholm (dnr 2019-02519) (Paper I & II). Patients and participants 
provided their written informed consent to participate in this study.  The zebrafish study was 
approved by the Ethical Review Board, Stockholm Animal Research Committee (dnr 19204-
2017) and by the Swedish Board of Agriculture (Paper I). The clinical study involving 
collection of BAL fluid from healthy individuals was performed in accordance with the 
Helsinki declaration after approval by the ethics committee, Regional Ethical Review Board in 
Gothenburg, Sweden (Dnr. 618-02, 065-04 and 683-07). Written informed consent was 
obtained prior to inclusion in the study (Paper II). The materials and methods in Paper III did 
not require any ethical permission since all experiments were in vitro only and only 




11.4 STATISTICAL ANALYSES 
All statistical analyses are described in the corresponding Papers I-III. GraphPad Prism 
software (GraphPad Software Inc., La Jolla, CA) were used for statistical analyses. In general, 
the distribution of data is determined and the number of groups different tests were used. T-test 
or Mann-Whitney U test was used to compare between two groups, whereas, ANOVA was 











12 RESULTS AND DISCUSSION  
For more details on the results and discussion, please refer to Papers I, II and III. 
Paper I: Effects of the Antimicrobial Peptide LL-37 and Innate Effector Mechanisms on 
Colistin-Resistant Klebsiella pneumoniae with mgrB Insertions 
Colistin, also known as polymyxin E, is a polypeptide antibiotic that is cationic in charge and 
attacks the negatively charged bacterial membrane (86). Due to extensive and unregulated use 
of colistin in clinical and animal farming settings many bacteria developed resistance to this 
drug, including Klebsiella pneumoniae (Kpn) (87). Colistin is the last resort antibiotic that is 
used in the clinic to treat multi-drug resistant bacteria and therefore emergence of colistin 
resistant bacterial strains is of most concern and a huge threat to humans worldwide. Colistin 
and LL-37 are both cationic in charge and they initially target the negatively charged parts of 
the bacterial membrane (60). Therefore, there is a potential risk of cross-resistance between 
colistin and LL-37, but previous data on this topic is not conclusive.  
In this study we compared two clinical Kpn carbapenem-resistant isolates that were genetically 
similar but differed in their colistin sensitivity, one isolate OM124 (Col-R) was colistin 
resistant (MIC 16 µg/ml) and the other isolate OM322, was colistin sensitive (Col-S) (MIC less 
than 1 µg/ml). Based on our gene sequencing data it was revealed that OM124 isolate had an 
inactivation with an insertion element in the mgrB gene as a likely mechanism of acquired 
colistin-resistance. The alterations in the mgrB gene, which encodes a negative feedback 
regulator on the PhoPQ system, is associated with LPS modifications leading to a reduction of 
the negative charge of LPS and thus, cause a phenotypic colistin resistance (88).  
To test the hypothesis that there is cross-resistance between colistin and LL-37, we performed 
a colony count assay. Notably, at 100 µg/ml of the LL-37 peptide, the Col-R isolate was 
significantly less susceptible to LL-37 when compared to Col-S (p = 0.0098). This was 
followed by comparing the effect of 100 µg/ml LL-37 against additional Col-R isolates (n = 8) 
with mgrB gene insertion elements and against Col-S isolates (n = 9) lacking this insertion. 
Indeed, these results indicate that there is cross-resistance between colistin and LL-37 in Col-
R strains, but only at high concentrations (above 50 µg/ml).  
Mutations in genes that cause antibiotic resistance usually target important biological and 
physiological properties in the bacteria, which might have negative side effects on the growth 
and survival in normal environments lacking antibiotics (89). Therefore, we investigated if the 
gain of colistin resistance caused a loss of fitness in relation to factors in the innate immune 
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system. We used whole blood, which provides a physiological condition, since it contains a 
complex mixture of immune cells and factors, such as white blood cells, platelets and proteins 
of the complement system. We found that colistin-resistance in Col-R strain OM124 did not 
exhibit any cost of fitness compared to Col-S OM322 strain. They were both similarly sensitive 
to be killed by whole blood and the complement system (human serum). In order to translate 
these results to an in vivo system, we tested the Col-R and Col-S strains in an infection model 
of zebrafish embryos. We selected this model since it is an established model of the innate 
immune system. Interestingly, in the zebrafish the adaptive immune cells do not mature until 4 
to 6 weeks after hatching, whereas the innate immune cells are available as soon as one day 
post-fertilization (90). Based on our experiments, we found no differences in survival nor in 
pathogenicity between the Col-R and Col-S strains. These results suggest that mutations in the 
mgrB gene due to insertion elements had no effects on bacterial fitness in relation to the innate 
immune system. Based on these results we concluded that the observed cross-resistance at high 
LL-37 concentrations most likely play a limited role during physiological conditions in vivo.  
Paper II: Studies on citrullinated LL-37: detection in human airways, antibacterial effects 
and biophysical properties  
During inflammation the level of activated PAD enzymes increase, which result in 
citrullination of various arginine-rich proteins and peptides, including the positively charged 
histones. In the same inflammatory milieu, plenty of AMPs are released from neutrophils and 
epithelia. Due to the close proximity of LL-37 to PAD enzymes and the presence of arginine 
residues in LL-37, it is highly likely that LL-37 will become citrullinated. However, the impact 
of citrullination on the biophysical and biological properties of LL-37 is not fully explored. 
Therefore, in this study we aimed to detect citrullinated forms of the LL-37 peptide in human 
BAL fluid obtained from healthy volunteers after intra-bronchial exposure to E. coli LPS as a 
proof-of-concept on the occurrence of citrullination on LL-37 in vivo. First, a peptide-protein 
extract was made from pooled BAL-fluid collected from the healthy volunteers. Next, the 
extract was separated using reversed phase HPLC and fractions were collected and further 
analyzed by dot-blot analysis with a monoclonal antibody against native LL-37 and a 
polyclonal antibody against LL-37Cit5. Notably, we were able to detect both native LL-37 as 
well as LL-37 Cit5 in the fractions. To rule out unspecific immunoreactivity, we employed the 
sensitive analysis of targeted LC-MS/MS of selected BAL fractions. Indeed, we could confirm 
that both native LL-37 and citrullinated LL-37 were present in BAL fluid samples. Previous 
studies suggested the presence of the citrullinated form of LL-37 in biological samples, but the 
results were not fully confirmed with LC-MS/MS and thus, not fully conclusive. Therefore, 
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our study is the first to actually unequivocally demonstrate the presence of citrullinated LL-37 
in a biological sample from humans. Nevertheless, the methods used (dot blot analysis and LC-
MS/MS) did not give any quantitative measurements of LL-37 and its citrullinated form(s). 
However, these results represent a valuable proof on the existence of LL-37 citrullination in 
human airways.  
The interactions of LL-37 to membranes is highly dependent on both electrostatic and 
hydrophobic interactions (46). Any disturbance in these features might have an effect on the 
biological functions of the peptide. Citrullination leads to reduction in the overall positive 
charge of the peptide, which potentially could reduce its interactions with bacterial membranes. 
Thus, we tested the antibacterial activity of multiple synthetic variants of citrullinated LL-37 
against E. coli. The native peptide exhibited potent antibacterial activity against E. coli in a 
dose-dependent manner. However, the fully citrullinated peptide had no antibacterial activity, 
even at concentrations as high as 80 µM. Citrullinating one or more arginine residues affected 
the antibacterial activity of LL-37 dramatically. Via electron microscopy studies we showed 
that, in contrast to native LL-37, fully citrullinated LL-37 had no effects on the intracellular 
structure of E. coli. Next, we tested whether the peptides could bind to the surface of bacteria 
using fluorescently labelled peptides and confocal microscope. Notably, LL-37Cit5 failed to 
bind to the surface of E. coli, whereas the native peptide exhibited a clear binding to the 
bacterial surface. We concluded from these results that the positive charge of LL-37 is a key 
factor for its binding to bacterial membranes and consequently for its antibacterial activity.  
In addition, we studied the interaction of native and fully citrullinated LL-37 with different 
components of the bacterial membrane. Using the isothermal titration calorimetry analysis, we 
determined a more enthalpy-driven interaction between native LPS molecules compared to 
fully citrullinated LL-37 peptides. Mass spectrometry analysis showed that the binding affinity 
of LL-37Cit5 to the anionic phospholipid micelles containing POPG was reduced compared to 
native LL-37.  Furthermore, we studied the secondary structure of peptides upon interaction 
with negatively charged large unilamellar vesicles (LUVs). Based on the CD spectra, peptides 
mixed with LUVs exhibited an increased helical content of both native and citrullinated LL-37 
with an overall higher helical content of citrullinated LL-37. In addition, the helical content of 
both peptides slightly increased upon interaction with an increasing concentration of LPS 
molecules. Taken together, citrullination impaired the antibacterial activity of LL-37. 
However, our data indicated that the interaction of LL-37 with LPS and phospholipids were 
not affected by citrullination. One way to explain this unexpected finding is that the interaction 
between LL-37 and LPS/phospholipids could be through hydrophobic interactions but this 
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interaction is insufficient for the disturbance of the bacterial membrane. In fact, citrullinated 
LL-37 is slightly more hydrophobic than native LL-37 and could thus, interact more strongly 
with LPS. However, this interaction does not seem to be involved in bacterial killing, since 
LL37Cit5 was inactive against gram-negative bacteria.  
Paper III: Citrullination alters the antibacterial and anti-inflammatory functions of the 
antimicrobial peptide canine cathelicidin K9CATH in vitro  
K9CATH is a cationic AMP found in dogs (canine=K9) sharing similarities with human LL-
37 by virtue of its positive charge at neutral pH, its ability to adopt a helical secondary structure 
as well as its antibacterial and anti-inflammatory functions (40, 42). K9CATH contains five 
arginine residues, similarly to LL-37 and could thus be subjected to citrullination in vivo. PAD 
enzymes are found in many animal species such as bony fish, frogs, and chickens, suggesting 
that citrullination has an important mechanism in nature (67). Given the need for additional 
models to study cathelicidin biology and citrullination, we designed a study to test the impact 
of citrullination on the dog cathelicidin K9CATH.  
In this study, to test whether K9CATH is prone to be citrullinated, we exposed the synthetic 
peptide K9CATH to human recombinant PAD2 and PAD4 enzymes at different time-points 
(30 – 240 min). Subsequently, using a LC-MS/MS analysis we first used synthetic peptides of 
K9CATH and K9CATHCit5 to study their ionization and fragmentation characteristics as a 
reference and then we continued with the in-vitro citrullinated K9CATH. We found that both 
PADs catalyzed citrullination of K9CATH starting from 30 min after incubation and the level 
of citrullinated variants increased with time. Interestingly, we found that PAD2 citrullinated 4 
arginine residues starting from 60 min, whereas PAD4 citrullinated only 3 arginine residues 
after 120 min. These results indicated that the PAD2 enzyme was more efficient in 
citrullinating K9CATH than the PAD4 enzyme. Next, we set out to test the effects of 
citrullination on the anti-inflammatory activity of K9CATH peptides exposed to PAD2 or 
PAD4. Peptides were incubated with LPS (100 ng/ml) before their addition to macrophages 
(RAW264.7 cells). After 24 h incubation, cell supernatants were used to study the anti-
inflammatory activities of the peptides. In contrast to native K9CATH, exposing K9CATH to 
the activity of PAD2 reduced the capacity to neutralize LPS-mediated NO production. 
However, PAD2 had no effects on TNF-a and IL-6 release by macrophages. We observed that 
exposing the peptide to PAD4 had no effects on its ability to neutralize LPS-mediated pro-
inflammatory effects on macrophages.  
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Next, we studied the effects of citrullination on the antibacterial activity of K9CATH. Based 
on the colony count assay against gram negative E. coli and P. multocida we found that 
citrullination profoundly affected K9CATH  ability to inhibit bacterial growth even at the high 
concentration of 80 µM. Full citrullination affected the ability of the K9CATH peptide to cause 
leakage of the bacterial membrane in both E. coli and P. multocida. In addition, we 
hypothesized that citrullinated K9CATH potentially could cause killing of E. coli with different 
LPS-structures. Thus, we obtained a collection of E. coli with different LPS components: E. 
coli 25922 had a complete LPS-structure, E coli MG1655 had an LPS-structure with no O-
antigens, and E. coli DA26796 lacked the outer core-OS and O-antigen of LPS. Interestingly, 
K9CATHCit5 was not able to kill any of these strains, despite their different LPS-structures. 
These results suggest that the electrostatic interaction between the peptide and bacteria is a key 
factor for the antibacterial activities of K9CATH. This finding validates the previous 
observations of citrullinated LL-37 in Paper II.  
Next, we studied whether the degree of citrullination had any impact on the anti-inflammatory 
activity exerted by synthetic K9CATH peptides. To that end, we stimulated murine and canine 
macrophage cell lines with LPS (100 ng/ml) pre-incubated with different peptides for 24 hours, 
including native and citrullinated K9CATH and LL-37 peptides (5 µM). We found that the 
ability of citrullinated peptides to neutralize LPS-mediated proinflammatory activity was 
reduced in comparison to native K9CATH or native LL-37. The level of reduction in this 
activity was influenced by the number of citrullinated arginine residues in each peptide.  
Finally, the hemolytic activity of the fully citrullinated peptide was tested against human red 
blood cells. We found that in contrast to the high hemolysis rate observed for the native peptide, 
the citrullinated peptide did not cause hemolysis to cells even at high concentrations (80 µM).  
Based on our results, we concluded that citrullination of K9CATH profoundly affected the 
biological activities of the peptide due to loss of the overall positive charge. However, further 
studies in animal models are required to better understand the role of citrullination in 
physiological and pathological conditions. Furthermore, the field of PAD regulation using 
PAD-inhibitors to treat autoimmune diseases and other inflammatory disorders is gaining much 
interest in the recent years. Consequently, additional molecular and mechanistic studies on 
PAD regulation are warranted.  
Overall, Paper I-III describe which factors that may define the interactions between 
antimicrobial peptides and bacterial membranes. In Paper I, we reported the bacterial side of 
this interaction, where potential cross-resistance between colistin and LL-37 was studied. The 
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mgrB-mutation in certain bacteria cause colistin-resistance by reducing the negative charge of 
the LPS-structure, which subsequently impair the interaction between colistin and the bacterial 
surface and cause phenotypic resistance to this drug. The same mechanism appears to be 
involved in how LL-37 interact with bacterial membranes. In Papers II and III, I shifted focus 
to the host and studied how endogenous enzymes (PADs) could reduce the net charge of the 
peptide, via citrullination of arginine-residues. Notably, the loss of the net charge in both LL-
37 and the dog orthologue K9CATH, severely impaired the antibacterial effect of these 
peptides. Thus, citrullination is a powerful regulator of AMP-function. Most of the experiments 
in paper II and III were performed in vitro. However, it should be noted that we could identify 
citrullinated LL-37 in human BAL-fluid, which strongly indicates that citrullination of AMPs 




The main findings of the presented work can be summarized as following: 
 
1. There is cross-resistance between colistin and LL-37 at concentrations above 
50 µg/ml in Kpn clinical isolates with colistin-resistance due to mgrB-insertion. 
No differences in the survival rate between the Col-R and Col-S isolates in 
blood, serum or in the zebrafish infection model were observed. (Paper I) 
 
2. Citrullinated variants of LL-37 are present in human airways. Citrullination 
abrogates the antibacterial activity of LL-37. The positive charge of LL-37 is 
essential for bacterial killing. (Paper II) 
 
3. The K9CATH peptide is prone to be citrullinated by PAD enzymes in vitro. In 
addition, citrullination impaired the antibacterial and LPS-neutralization 











14 FUTURE PERSPECTIVES 
Increasing emergence of bacterial resistance to conventional antibiotics is a global concern in 
the human and animal healthcare, leading to an increase in the need for novel antimicrobial 
drugs (22). Research on the use of AMPs as novel antibiotics is gaining much attention in the 
scientific field. These peptides are of great interest by virtue of their broad-spectrum 
antibacterial activities against several pathogens. In addition, AMPs with different mechanism 
of action on pathogens make the development of resistance difficult. Cationic AMPs mainly 
target the negatively charged membranes of bacteria but in addition they target anionic 
intracellular components, such as ribosomes and DNA, thereby inhibiting the growth of target 
pathogens (91, 92). The application of AMPs as therapeutics are mainly by direct 
administration of the AMP to the patient, either systematic or topically. For example, 
Polymyxin B (topical treatment) and colistin (systemic or inhaled) are examples of peptide 
antibiotics that are used in the clinic. The other proposed way to exploit AMPs in the fight 
against infections, involves boosting of the innate immune system to induce AMP-expression 
using nutrients, such as Vitamin D3 and phenylbutyrate (93). However, there is a rising 
argument in the scientific community on the risk of emergence of bacterial resistance to specific 
AMPs due to continuous exposure to bacteria and selection of resistant mutants. There is a risk 
that resistance against one AMP may lead to cross-resistance to other innate immune AMPs or 
even to conventional antibiotics, such as colistin (94). Therefore, there is a need to consider 
this risk when designing novel therapies involving AMPs. Our findings on cross-resistance 
between colistin and LL-37 at high concentrations in clinical colistin-resistant Kpn-isolates 
may have several interesting implications.  First, increased levels of LL-37 during pathological 
conditions, such as infections might lead to selection pressure for colistin-resistant strains. 
Therefore, it would be interesting to study the virulence of colistin-resistant strains in infections 
models of healthy and inflamed animal models. It would also be interesting to study the survival 
of those strains in blood and plasma isolated from patients with high circulating levels of LL-
37. On such disease is psoriasis, where the level of LL-37 is dramatically elevated in serum 
and may reach as high as 1366 µg/ml (95). If the cross-resistance has clinical importance, our 
results may lead to special considerations when colistin is administered to patients with 
elevated levels of LL-37, especially in intensive care units where colistin-resistant Kpn are 
thriving. This risk of pre-existing colistin-resistance could be high in these patients, and other 
treatment options should be chosen. 
On the host side, AMPs undergo several PTMs via different pathways. In recent years, a great 
interest has been focused on citrullination of proteins and peptides in association with 
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autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis and also 
associated with some types of cancer (96–98). In our studies on citrullinated LL-37 and 
K9CATH, we found that citrullination affect their biological functions, such as direct 
antibacterial activity. The results presented here may serve as a starting point for future studies 
on the role of AMP citrullination in health and disease in humans and animals. In fact, there 
are ongoing efforts to use PAD inhibitors as a way to regulate excessive activation of these 
enzymes in chronic diseases (99–101). However, the physiological functions of PAD enzymes 
in innate immunity, particularly on AMPs, are not fully understood. Thus, it is of great interest 
to study the effects of citrullination, not only on the antibacterial and immunomodulatory 
functions of AMPs, but also on additional biological functions of AMPs, such as angiogenesis, 
wound healing and anticancer properties. This would give us a better picture to evaluate the 
effects of PAD enzymes and to learn how to use PAD inhibitors in therapy. Further 
investigations using in vivo systems of PAD-deficient animal models or patients with altered 
expression of PADs (induced or down-regulated) could facilitate such studies. Since PAD 
enzymes are found in many animal species (67), it would be great to expand the studies of 
citrullination to other living organisms, such as zebrafish, birds and reptiles. These organisms 
have relatively less complex immune systems compared to mammals and they are easy to 
manipulate genetically. In addition, PAD deficient cell-lines or PAD-labelled cells could be 
obtained from these organisms for better visualization and localization. The half-life of these 
organisms is shorter than mammals and also cheaper to keep and maintain these model 
organisms in a laboratory set up. A recent study on halibut fish proved the presence of PAD 
enzymes and that innate immune factors, such as complement proteins C3 and C4 can be 
citrullinated (102). It would be interesting to detect citrullinated AMPs in the zebrafish, for 
example the defensin peptides. This would enable studies on the effects of citrullination in vivo 
and in vitro. Since cathelicidins have not yet been detected in zebrafish, there is also a great 
opportunity to dig deeper into the zebrafish genome and search for this gene or close 
orthologues. Although the fish-model is much different from humans, there are many 
conserved genes and shared mechanisms between the two species. Therefore, it is important to 
perform basic research in simple model organisms and learn about the fundamental 
mechanisms behind the function of PADs and the details of innate immunity. This will open 




14.1 FUTURE PERSPECTIVES – A PERSONAL NOTE 
My background is in animal and veterinary sciences and I am planning to continue along this 
path both in research and education. I have thought of several aspects that I have learned from 
my PhD work and would like to implement in my future career. In Oman, camels are highly 
precious animals since they represent the Omani and the Arabic heritage. They are used mainly 
for racing but also for their meat and milk. These animals are unique and strong, they tolerate 
the harsh environment in the desert but they also endure many infectious diseases. In addition, 
their immune system is quite unique compared to other domestic animals. However, it is not 
fully explored, in particular there is a lack of knowledge about the innate immune system in 
camels. My plan is to start to search for cathelicidins and other AMPs in camels. I will use the 
fractionation of biological samples using the reversed phase-HPLC method and then test each 
fraction for their antibacterial activity using a simple inhibition zone assay. Depending on the 
results we could send the positive fractions for protein and peptide detection via electro spray 
mass-spectrometry (LC-MS/MS). In addition, I would like to study PAD enzymes and their 
contribution to the innate immunity of camels. More specifically I would like to study the role 
of PADs in the process of NETosis. Another aspect that I would like to explore is to study the 
usage of antibiotics as food additives in animal farms and relate it to the emergence of antibiotic 
resistant bacteria in animals and humans.  
Finally, I am also interested in wild animals and the migratory birds in Oman. Due to the unique 
geographical features and location of Oman, millions of migrating birds transit in Oman every 
year. It would be interesting to study the presence of antibiotic resistant strains in these birds 
and to relate it to the microbiota in resident birds and animals. This will be important to know 
from an environmental point of view.  
In the end, this PhD-period has been quite a journey and I have learned lots of laboratory skills 
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